MA57599B1 - Semaglutide pour le traitement de la démence d'alzheimer - Google Patents
Semaglutide pour le traitement de la démence d'alzheimerInfo
- Publication number
- MA57599B1 MA57599B1 MA57599A MA57599A MA57599B1 MA 57599 B1 MA57599 B1 MA 57599B1 MA 57599 A MA57599 A MA 57599A MA 57599 A MA57599 A MA 57599A MA 57599 B1 MA57599 B1 MA 57599B1
- Authority
- MA
- Morocco
- Prior art keywords
- semaglutide
- dementia
- alzheimer
- treatment
- glp
- Prior art date
Links
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title abstract 2
- 229950011186 semaglutide Drugs 0.000 title abstract 2
- 108010060325 semaglutide Proteins 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 238000013160 medical therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207501 | 2019-11-06 | ||
| EP20186623 | 2020-07-20 | ||
| PCT/EP2020/081087 WO2021089678A1 (en) | 2019-11-06 | 2020-11-05 | Glp-1 receptor agonists in dementia |
| EP20803489.2A EP4054620B1 (en) | 2019-11-06 | 2020-11-05 | Semaglutide in the treatment of alzheimer's dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA57599B1 true MA57599B1 (fr) | 2024-06-28 |
Family
ID=73172681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA57599A MA57599B1 (fr) | 2019-11-06 | 2020-11-05 | Semaglutide pour le traitement de la démence d'alzheimer |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20220280612A1 (https=) |
| EP (2) | EP4414031A3 (https=) |
| JP (2) | JP7670698B2 (https=) |
| KR (1) | KR20220110731A (https=) |
| CN (1) | CN114728042A (https=) |
| AU (1) | AU2020377469A1 (https=) |
| BR (1) | BR112022007721A2 (https=) |
| CA (1) | CA3154744A1 (https=) |
| ES (1) | ES2984177T3 (https=) |
| HR (1) | HRP20241052T1 (https=) |
| HU (1) | HUE067514T2 (https=) |
| IL (1) | IL291876A (https=) |
| MA (1) | MA57599B1 (https=) |
| MX (1) | MX2022004779A (https=) |
| PH (1) | PH12022550842A1 (https=) |
| PL (1) | PL4054620T3 (https=) |
| RS (1) | RS65780B1 (https=) |
| TW (1) | TWI890704B (https=) |
| WO (1) | WO2021089678A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL291876A (en) | 2019-11-06 | 2022-06-01 | Novo Nordisk As | Receptor agonists in glp-1 type dementia |
| KR20220132606A (ko) * | 2020-01-30 | 2022-09-30 | 일라이 릴리 앤드 캄파니 | 둘라글루티드의 치료 용도 |
| US20240050531A1 (en) * | 2020-12-16 | 2024-02-15 | The Chinese University Of Hong Kong | A method for reversing aging brain functional decline |
| KR20240123816A (ko) | 2021-12-02 | 2024-08-14 | 쾨벤하운스 유니버시테트 | 퇴행성 신경 질환의 치료를 위한 펩티드-약물 접합체 |
| WO2024179606A1 (zh) * | 2023-03-02 | 2024-09-06 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| CN120131965A (zh) * | 2025-04-10 | 2025-06-13 | 瓯江实验室 | Glp-1受体激动剂治疗阿尔茨海默病的用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| AU3357800A (en) | 1999-02-05 | 2000-08-25 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
| WO2001092206A1 (en) | 2000-06-02 | 2001-12-06 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN101258163B (zh) | 2005-06-30 | 2013-08-21 | 益普生制药股份有限公司 | Glp-1药物组合物 |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| US8501693B2 (en) | 2006-08-04 | 2013-08-06 | Amylin Pharmaceuticals, Llc | Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen |
| BRPI0716539A2 (pt) | 2006-09-07 | 2016-11-01 | Emisphere Tech Inc | métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| SI2651398T1 (en) * | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS |
| PL2696687T3 (pl) | 2011-04-12 | 2017-06-30 | Novo Nordisk A/S | Pochodne podwójnie acylowanej GLP-1 |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| EP2866825B1 (en) * | 2012-07-01 | 2020-04-08 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| ES2741507T3 (es) | 2014-04-07 | 2020-02-11 | Novo Nordisk As | Compuestos de glp-1 acilados doblemente |
| WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| CN108697768B (zh) | 2015-12-23 | 2022-07-22 | 约翰霍普金斯大学 | 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法 |
| US20190142905A1 (en) | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| IL291876A (en) | 2019-11-06 | 2022-06-01 | Novo Nordisk As | Receptor agonists in glp-1 type dementia |
| JP7761567B2 (ja) | 2020-02-18 | 2025-10-28 | ノヴォ ノルディスク アー／エス | 医薬製剤 |
-
2020
- 2020-11-05 IL IL291876A patent/IL291876A/en unknown
- 2020-11-05 PH PH1/2022/550842A patent/PH12022550842A1/en unknown
- 2020-11-05 KR KR1020227015440A patent/KR20220110731A/ko active Pending
- 2020-11-05 EP EP24175772.3A patent/EP4414031A3/en active Pending
- 2020-11-05 JP JP2022521146A patent/JP7670698B2/ja active Active
- 2020-11-05 CA CA3154744A patent/CA3154744A1/en active Pending
- 2020-11-05 HU HUE20803489A patent/HUE067514T2/hu unknown
- 2020-11-05 CN CN202080076976.0A patent/CN114728042A/zh active Pending
- 2020-11-05 MA MA57599A patent/MA57599B1/fr unknown
- 2020-11-05 MX MX2022004779A patent/MX2022004779A/es unknown
- 2020-11-05 AU AU2020377469A patent/AU2020377469A1/en active Pending
- 2020-11-05 BR BR112022007721A patent/BR112022007721A2/pt unknown
- 2020-11-05 HR HRP20241052TT patent/HRP20241052T1/hr unknown
- 2020-11-05 RS RS20240863A patent/RS65780B1/sr unknown
- 2020-11-05 PL PL20803489.2T patent/PL4054620T3/pl unknown
- 2020-11-05 WO PCT/EP2020/081087 patent/WO2021089678A1/en not_active Ceased
- 2020-11-05 ES ES20803489T patent/ES2984177T3/es active Active
- 2020-11-05 EP EP20803489.2A patent/EP4054620B1/en active Active
- 2020-11-06 TW TW109138851A patent/TWI890704B/zh active
-
2022
- 2022-05-04 US US17/736,116 patent/US20220280612A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,485 patent/US20230302094A1/en not_active Abandoned
-
2024
- 2024-01-30 US US18/426,412 patent/US20240207364A1/en active Pending
- 2024-12-04 JP JP2024211204A patent/JP2025027130A/ja active Pending
- 2024-12-12 US US18/979,068 patent/US12539326B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230302094A1 (en) | 2023-09-28 |
| HRP20241052T1 (hr) | 2024-11-08 |
| EP4054620A1 (en) | 2022-09-14 |
| EP4414031A3 (en) | 2025-02-05 |
| EP4054620C0 (en) | 2024-05-29 |
| CA3154744A1 (en) | 2021-05-14 |
| HUE067514T2 (hu) | 2024-10-28 |
| EP4414031A2 (en) | 2024-08-14 |
| JP2023500032A (ja) | 2023-01-04 |
| RS65780B1 (sr) | 2024-08-30 |
| WO2021089678A1 (en) | 2021-05-14 |
| CN114728042A (zh) | 2022-07-08 |
| TW202519256A (zh) | 2025-05-16 |
| US12539326B2 (en) | 2026-02-03 |
| KR20220110731A (ko) | 2022-08-09 |
| ES2984177T3 (es) | 2024-10-29 |
| US20220280612A1 (en) | 2022-09-08 |
| TW202118509A (zh) | 2021-05-16 |
| AU2020377469A1 (en) | 2022-04-28 |
| MX2022004779A (es) | 2022-06-14 |
| JP7670698B2 (ja) | 2025-04-30 |
| EP4054620B1 (en) | 2024-05-29 |
| JP2025027130A (ja) | 2025-02-26 |
| IL291876A (en) | 2022-06-01 |
| TWI890704B (zh) | 2025-07-21 |
| US20250099549A1 (en) | 2025-03-27 |
| US20240207364A1 (en) | 2024-06-27 |
| PL4054620T3 (pl) | 2024-10-14 |
| PH12022550842A1 (en) | 2023-10-09 |
| BR112022007721A2 (pt) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57599B1 (fr) | Semaglutide pour le traitement de la démence d'alzheimer | |
| MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
| Spudich | Immune activation in the central nervous system throughout the course of HIV infection | |
| Boada et al. | Neuropsychological, neuropsychiatric, and quality‐of‐life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study | |
| Shah et al. | Acquired neurosyphilis presenting as movement disorders | |
| MA40224A (fr) | Anticorps se liant aux protofibrilles ass améliorés | |
| MA43828A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| MA45543B1 (fr) | Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations | |
| MX2021010696A (es) | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. | |
| MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| EA202190569A1 (ru) | Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla | |
| FR3063645B1 (fr) | Acefapc pour le traitement des maladies acetylcholine dependantes | |
| MX2019006141A (es) | Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. | |
| EP3960858A4 (en) | SMALL RNA DRUG USED TO PREVENT AND TREAT INFLAMMATION-RELATED DISEASES AND COMBINATIONS THEREOF | |
| EA202190755A1 (ru) | Агенты для терапии и диагностики рака | |
| MA32299B1 (fr) | Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedarone | |
| MA56998B1 (fr) | Traitement de symptômes induits par le cycle menstruel | |
| MA54276B1 (fr) | Montélukast destinée au traitement de l'arthrose de la main | |
| EP3443984A4 (en) | PHARMACEUTICAL COMPOSITION FOR REDUCING THE SYMPTOMS AND THE SERIOUS DEGREE OF RESPIRATORY INFECTION BY human metapneumovirus (hMPV) WITH AT LEAST ONE FUNCTION OF TSLP- AND / OR TSLPR- AND / OR OX40L- AND / OR CD177-MOLECULE neutralizing agent AND PHARMACEUTICAL ACCEPTABLE ALTERNATIVE FUEL AND USE THEREOF | |
| Huang et al. | Rosiglitazone suppresses HIV-1 Tat-induced vascular inflammation via Akt signaling | |
| MA33455B1 (fr) | Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux | |
| MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
| FR3073398B1 (fr) | Triterpenes pentacycliques dans le traitement d'une pathologie bucco-dentaire | |
| Chirumbolo et al. | Post‑COVID or long‑COVID? That is the question | |
| CA3156182A1 (en) | METHODS FOR PROCESSING S1P1 RECEIVER BOUND STATES |